Klaas Koop

1.4k total citations · 1 hit paper
21 papers, 1.1k citations indexed

About

Klaas Koop is a scholar working on Genetics, Surgery and Nephrology. According to data from OpenAlex, Klaas Koop has authored 21 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 4 papers in Surgery and 4 papers in Nephrology. Recurrent topics in Klaas Koop's work include Metabolism and Genetic Disorders (4 papers), Renal Diseases and Glomerulopathies (4 papers) and Renal Transplantation Outcomes and Treatments (3 papers). Klaas Koop is often cited by papers focused on Metabolism and Genetic Disorders (4 papers), Renal Diseases and Glomerulopathies (4 papers) and Renal Transplantation Outcomes and Treatments (3 papers). Klaas Koop collaborates with scholars based in Netherlands, United States and Japan. Klaas Koop's co-authors include Emile de Heer, Michael Eikmans, Hans J. Baelde, Jan A. Bruijn, Hiroshi Kawachi, Johan T. den Dunnen, Judith C. van Deutekom, Annemieke Aartsma‐Rus, Anneke A. M. Janson and Lorna Paul and has published in prestigious journals such as New England Journal of Medicine, Kidney International and Journal of the American Society of Nephrology.

In The Last Decade

Klaas Koop

18 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Local Dystrophin Restoration with Antisense Oligonucleotide PRO051

2007 577 citations Judith C. van Deutekom, Anneke A. M. Janson et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Klaas Koop

Since Specialization

Citations

This map shows the geographic impact of Klaas Koop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaas Koop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaas Koop more than expected).

Fields of papers citing papers by Klaas Koop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaas Koop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaas Koop. The network helps show where Klaas Koop may publish in the future.

Co-authorship network of co-authors of Klaas Koop

This figure shows the co-authorship network connecting the top 25 collaborators of Klaas Koop. A scholar is included among the top collaborators of Klaas Koop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaas Koop. Klaas Koop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reducing False Positives in Newborn Screening: The Role of Perinatal Factors in the Dutch NBS Program 2025 ·Metabolites ·(unknown), (unknown), Patricia Hall, Wouter F. Visser, Klaas Koop, Annet M. Bosch, M. Rebecca Heiner‐Fokkema, Monique G.M. de Sain–van der Velden, (unknown)	0
2	Rethinking Newborn Screening: A Case of GALM Deficiency 2025 ·International Journal of Neonatal Screening ·(unknown), Silvia Radenkovic, Klaas Koop, Hubertus C.M.T. Prinsen, (unknown)	0
3	Maleic acid is a biomarker for maleylacetoacetate isomerase deficiency; implications for newborn screening of tyrosinemia type 1 2023 ·Journal of Inherited Metabolic Disease ·(unknown), (unknown), Marelle J. Bouva, (unknown), (unknown), (unknown), Monique G. de Sain-van der Velden, Klaas Koop, Alessandro Rossi, James A. Thomas, (unknown), Mensiena B. G. Kiewiet, Paula J. Waters, Denis Cyr, (unknown), Anita Boelen, F. J. van Spronsen, M. Rebecca Heiner‐Fokkema	7
4	A False-Negative Newborn Screen for Tyrosinemia Type 1—Need for Re-Evaluation of Newborn Screening with Succinylacetone 2023 ·International Journal of Neonatal Screening ·(unknown), (unknown), M. Rebecca Heiner‐Fokkema, Frank A.J.A. Bodewes, (unknown), József Zsíros, Koen van Aerde, Klaas Koop, Francjan J. van Spronsen, (unknown)	6
5	Biochemical Studies in Fibroblasts to Interpret Variants of Unknown Significance in the ABCD1 Gene 2021 ·Genes ·(unknown), P. A. W. Mooyer, Inge M. E. Dijkstra, Conny Dekker, (unknown), (unknown), Maura Ruzhnikov, Keith Van Haren, Nelson L.S. Tang, Klaas Koop, Michèl A.A.P. Willemsen, Joannie Hui, Frédéric M. Vaz, Merel S. Ebberink, Marc Engelen, Stephan Kemp, Sacha Ferdinandusse	8
6	Genetic defect of the sodium‐dependent multivitamin transporter: A treatable disease, mimicking biotinidase deficiency 2019 ·JIMD Reports ·(unknown), (unknown), Judith Jans, Koen L.I. van Gassen, (unknown), Klaas Koop, Gepke Visser	16
7	Increased dynamin expression precedes proteinuria in glomerular disease 2018 ·The Journal of Pathology ·Ramzi Khalil, Klaas Koop, Reinhold Kreutz, Herman P. Spaink, Pancras C.W. Hogendoorn, Jan A. Bruijn, Hans J. Baelde	9
8	[Fever with a rash caused by chronic meningococcemia]. 2015 ·PubMed ·(unknown), Klaas Koop, M.T. Bousema, (unknown)	1
9	Cat Scratches or Flea Feces? 2013 ·The Journal of Pediatrics ·Klaas Koop, (unknown), (unknown), (unknown)	0
10	Hair-on-End 2013 ·American Journal of Tropical Medicine and Hygiene ·(unknown), Michael D. Shields, Klaas Koop	3
11	A case of recurrent toxin-mediated perineal erythema 2013 ·Archives of Disease in Childhood ·(unknown), (unknown), Klaas Koop, (unknown)	2
12	Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America 2011 ·Bone Marrow Transplantation ·(unknown), (unknown), (unknown), Klaas Koop, Claudia Sampor, (unknown), (unknown), Luis Castillo, Guillermo Chantada	28
13	C4d Staining In Renal Allograft Biopsies with Early Acute Rejection and Subsequent Clinical Outcome 2011 ·Clinical Journal of the American Society of Nephrology ·(unknown), Hanneke de Kort, Michael Eikmans, Klaas Koop, Hans J. Baelde, Marko J.K. Mallat, Kim Zuidwijk, Cees van Kooten, Emile de Heer, Natascha Goemaere, Frans H.J. Claas, Jan A. Bruijn, Johan W. de Fijter, Ingeborg M. Bajema, (unknown)	13
14	Glomerular hypertrophy precedes albuminuria and segmental loss of podoplanin in podocytes in Munich-Wistar-Frömter rats 2008 ·American Journal of Physiology-Renal Physiology ·Daphne H.T. IJpelaar, Angela Schulz, Klaas Koop, (unknown), Jan A. Bruijn, Dontscho Kerjaschki, Reinhold Kreutz, Emile de Heer	46
15	Selective Loss of Podoplanin Protein Expression Accompanies Proteinuria and Precedes Alterations in Podocyte Morphology in a Spontaneous Proteinuric Rat Model 2008 ·American Journal Of Pathology ·Klaas Koop, Michael Eikmans, Markus Wehland, Hans J. Baelde, Daphne H.T. IJpelaar, Reinhold Kreutz, Hiroshi Kawachi, Dontscho Kerjaschki, Emile de Heer, (unknown)	47
16	Local Dystrophin Restoration with Antisense Oligonucleotide PRO051 breakdown → 2007 ·New England Journal of Medicine ·Judith C. van Deutekom, Anneke A. M. Janson, Ieke B. Ginjaar, (unknown), Annemieke Aartsma‐Rus, (unknown), Johan T. den Dunnen, Klaas Koop, Anneke J. van der Kooi, Nathalie Goemans, Sjef J. de Kimpe, (unknown), (unknown), Gerard Platenburg, Jan J.G.M. Verschuuren, Gert‐Jan B. van Ommen	577
17	Genetic factors in progressive renal disease: the good ones, the bad ones and the ugly ducklings 2005 ·Nephrology Dialysis Transplantation ·Michael Eikmans, (unknown), Klaas Koop, Hans J. Baelde, Emile de Heer, Jan A. Bruijn	7
18	Differentiation between chronic rejection and chronic cyclosporine toxicity by analysis of renal cortical mRNA 2004 ·Kidney International ·Klaas Koop, René C. Bakker, Michael Eikmans, Hans J. Baelde, Emile de Heer, Leendert C. Paul, Jan A. Bruijn	18
19	Expression of Podocyte-Associated Molecules in Acquired Human Kidney Diseases 2003 ·Journal of the American Society of Nephrology ·Klaas Koop, Michael Eikmans, Hans J. Baelde, Hiroshi Kawachi, Emile de Heer, Lorna Paul, Jan A. Bruijn	249
20	Early Interstitial Accumulation of Collagen Type I Discriminates Chronic Rejection from Chronic Cyclosporine Nephrotoxicity 2003 ·Journal of the American Society of Nephrology ·René C. Bakker, Klaas Koop, Yvo W.J. Sijpkens, Michael Eikmans, Ingeborg M. Bajema, Emile de Heer, Jan A. Bruijn, Leendert C. Paul	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact